EUVIMEDEUVIMED entdecken
Beobachtungsstudie

To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution

Stefano Restaino, Carlo Ronsini, Giulia Pellecchia, Mario Fordellone, Giorgio Bogani, Antonino Ditto, Eugenio Solima, Stefano Uccella, Piercarlo Zorzato, Marco Petrillo, Giampiero Capobianco, Vito Chiantera und 5 weitere

European Journal of Surgical Oncology · 2026-11 · 52 (11) · 112076

DOI: 10.1016/j.ejso.2026.112076 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Surgical Oncology, 2026-11. Verfasst von Stefano Restaino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, It…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, CA-125 Antigen, Neoplasm Recurrence, Local, Membrane Proteins. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Cancer antigen 125 (CA125) has been proposed as a prognostic biomarker in endometrial cancer; however, its role in routine postoperative surveillance remains controversial. This study aimed to evaluate the clinical utility of serial CA125 measurements for detecting endometrial cancer recurrence and to identify a prognostically relevant cutoff value. METHODS: We conducted a retrospective observational cohort study of patients with endometrial cancer treated at a single ESGO-accredited institution. Serial CA125 levels were measured at regular intervals during postoperative surveillance. An optimal CA125 cutoff value was derived using receiver operating characteristic analysis based on CA125 levels measured at a predefined 18-month postoperative landmark in patients alive and recurrence-free at that time. Recurrence-free survival was subsequently analyzed using Kaplan-Meier methods. RESULTS: Patients with recurrence showed progressively higher CA125 levels than disease-free patients, with statistically significant differences emerging at 15 months (p-value = 0.014) and 18 months (p-value = 0.005) after surgery. A CA125 cutoff of 9.58 U/mL at 18 months best predicted recurrence. Based on this value, 105 patients were classified as low-risk and 49 as high-risk. ROC curve analysis demonstrated good discriminatory ability (AUC = 0.72, p-value < 0.001). Kaplan-Meier analysis showed significantly worse recurrence-free survival in patients with CA125 ≥ 9.58 U/mL compared to those with lower values (p-value = 0.02). CONCLUSION: Selective serial monitoring of CA125 during postoperative surveillance may help identify patients at increased risk of endometrial cancer recurrence and serve as an adjunct to imaging and guideline-based risk stratification, pending prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCA-125 AntigenNeoplasm Recurrence, LocalMembrane ProteinsFemaleHumansRetrospective StudiesAgedMiddle AgedBiomarkers, TumorROC CurvePrognosisDisease-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

BiomarkersCA-125 AntigenDisease-Free SurvivalEndometrial NeoplasmsLocalNeoplasm RecurrencePrognosisTumor

Substanzen

CA-125 AntigenBiomarkers, TumorMembrane Proteins

Autor:innen und Institutionen

  • Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; PhD School in Biomedical Sciences, Gender Medicine, Child and Wom…
  • Unit of Gynecologic Oncology, National Cancer Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione "G. Pascale", Naples, Italy.
  • Unit of Gynecology and Obstetrics, Policlinico Abano Terme, Abano Terme, Italy.
  • Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Medical Statistics Unit, Naples, Italy.
  • Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Gynecologic Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Aviano, PN, Italy.

Zitieren

APA

Restaino, S., Ronsini, C., Pellecchia, G., Fordellone, M., Bogani, G., Ditto, A., Solima, E., Uccella, S., Zorzato, P., Petrillo, M., Capobianco, G., Chiantera, V., Driul, L., Arcieri, M., Elhadi, M., Kim, J. H., & Vizzielli, G. (2026). To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution. European Journal of Surgical Oncology, 52(11), 112076. https://doi.org/10.1016/j.ejso.2026.112076

Vancouver

Restaino S, Ronsini C, Pellecchia G, Fordellone M, Bogani G, Ditto A, et al. To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution. European Journal of Surgical Oncology. 2026;52(11):112076. doi:10.1016/j.ejso.2026.112076

BibTeX
@article{Restaino2026,
  author = {Restaino, Stefano and Ronsini, Carlo and Pellecchia, Giulia and Fordellone, Mario and Bogani, Giorgio and Ditto, Antonino and Solima, Eugenio and Uccella, Stefano and Zorzato, Piercarlo and Petrillo, Marco and Capobianco, Giampiero and Chiantera, Vito and Driul, Lorenza and Arcieri, Martina and Elhadi, Muhammed and Kim, Ji-Hyun and Vizzielli, Giuseppe},
  title = {To be or not to be: The role of serial CA125 monitoring in early endometrial cancer recurrence detection, insights from an ESGO-accredited institution},
  journal = {European Journal of Surgical Oncology},
  year = {2026},
  volume = {52},
  number = {11},
  pages = {112076},
  doi = {10.1016/j.ejso.2026.112076}
}
Kostenlos starten →